Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age
ClinicalTrials.gov Identifier: NCT04946318
Novartis Reference Number: CCSJ117A12201E1
Last Update: May 17, 2022
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or high dose ICS plus LABA alone or with additional asthma controllers (additional controllers allowed: LTRA, LAMA, Theophylline and its derivatives), who have completed the prior phase llb study CCSJ117A12201C (NCT04410523).
Interventions
Eligibility Criteria
Inclusion Criteria:
All participants must have been treated with a fixed dose combination of fluticasone propionate/salmeterol in one of two doses in stable dose alone or with additional controllers at label approved dosage (allowed only: LTRA, LAMA, Theophylline or its derivatives).
Participants completing the Treatment period and Follow-up period of study CSJ117A12201C and continuing with study CCSJ117A12201E1 must have completed the Treatment period of CSJ117A12201C (i.e. did not discontinue blinded study treatment prematurely) and Follow-up period of study CSJ117A12201C.
Exclusion Criteria:
Participants who were enrolled into prior study CSJ117A12201C and developed a significant and/or permanent health condition during the prior study.
Participants who experienced a serious and drug-related AE in the prior study CSJ117A12201C.
Participants receiving any prohibited medications.
Participants with a history or current diagnosis of ECG abnormalities.
Pregnant or nursing (lactating) women.
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]